The challenge of frailty and sarcopenia in heart failure with preserved ejection fraction
Known adverse reactions: Mild gastrointestinal symptoms (transient nausea, vomiting, abdominal cramps, and diarrhea) have been reported
Epidermal growth factor receptor inhibition treats experimental autoimmune Encephalomyelitis
Over 17,000 patients in 41 countries who had previously experienced a heart attack, stroke and/or had peripheral artery disease were enrolled and followed for an average of 40 months after being randomly assigned to receive once weekly injections of semaglutide 2.4 mg or placebo
Clinical data from the landmark SURMOUNT-1 trial showed participants losing up to approximately 20% of their total body weight over 72 weeks, significantly more than what was achieved with older GLP-1 medications
Week 1-2: subtle changes During the first two weeks, most users don't see dramatic visible changes